WASHINGTON - The Trump administration will announce Tuesday that it has signed a US$354 million four-year contract with a new company in Richmond, Virginia, to manufacture generic medicines and pharmaceutical ingredients that are needed to treat Covid-19 but are now made overseas, mostly in India and China.
The project, he said,"will not only help bring our essential medicines home but actually do so in a way that is cost competitive with the sweatshops and pollution havens of the world." "There are not a lot of people wanting to bring back generic medicine manufacturing to the United States that has been lost to India and China over decades," said Dr Edwards, who described himself as a serial entrepreneur as well as a physician."You need someone like the federal government saying this is too important for us not to focus on."
Dr Edwards said his company would focus on"critical care medicines used to treat hospitalized patients with Covid-19," including"medicines that are used for sedation to help patients requiring ventilator support, pain management and certain essential antibiotics." Production has already begun at an Ampac facility, he said, while Phlow builds new plants.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: BusinessTimes - 🏆 15. / 51 اقرأ أكثر »